Screening of derivatives of 2-(benzoyilamino)(1-r-2-oxoindolin-3-ylidene)acetic acid under the conditions of acute hypobaric hypoxia
Keywords:antihypoxants, hypobaric hypoxia, derivatives of 2-(benzoyilamino)(1-R-2-oxoindolin-3-ylidene)acetic acid, mexidol
AbstractThe results of screening of 2-(benzoyilamino)(1-R-2-oxoindolin-3-ylidene)acetic acid derivatives on the antihypoxic activity are presented in the article. It has been determined that under the conditions of acute hypоbaric hypoxia compounds 4, 14 and 15 have shown the increase of the integral index of the antihypoxic activity of substances – the overall lifetime of animals at the “high-altitude plateau”. However, the mortality rate of animals reached 20% for compound 4, and it significantly exceeded the control data. At the same time, compound 14 by its antihypoxic activity significantly increased the overall lifetime of animals by 150% compared to the control data, but its effect was significantly weaker than the effect of the reference drug mexidol, which increased the lifetime of animals by 197% (p<0.05). For compound 15 the overall lifetime of animals increased by 186% compared to the control data (p<0.05) and did not differ significantly from that of the reference drug. The data obtained indicate that most of the substances studied – derivatives of 2-(benzoyilamino)(1-R-2-oxoindolin-3-ylidene)acetic acid – demonstrate certain antihypoxic properties, as well as derivatives of 2-(2-oxoindolin-3-ylidene)acetic acid previously researched. Moreover, only compound 15 corresponds to the antihypoxic efficacy of the reference drug, and by the index of recovery of the animals’ physical activity after their staying at the “high-altitude plateau” (the posture recovery time) it exceeds the effect of the antihypoxant drug mexidol.
Андреева Н.Н. // Мед. альманах. – 2009. – № 4 (9). – С. 193–197.
Березовский В.А. Гипоксия и индивидуальные особенности реактивности. – К.: Наук. думка, 1978. – 216 с.
Воронина Т.А. // Журн. неврол. и психиатр. им. С.С. Корсакова. – 2012. – № 12. – С. 86–90.
Евсеева М.А., Евсеев А.В., Правдивцев В.А. и др. // Обзоры по клин. фармакол. и лек. терапии. – 2008. – Т. 6, № 1. – С. 3–25.
Заморський І.І. // Одеський мед. журн. – 1998. – № 6 (50). – С. 23–25.
Зыкова С.С. // Вестник современ. клин. мед. – 2014. – Т. 7, вып. 2. – С. 70–73.
Катунина Н.П. // Наука и современность. – 2010. – № 5. – С. 298–300.
Колісник С.В., Кононенко Н.М., Гаман Д.В. та ін. // Вісник фармації. – 2011. – № 4 (68). – С. 64–66.
Лукьянова Л.Д. // Фізіол. журн. – 2003. – Т. 49, № 3. – С. 17–35.
Sevryukov O.V., Volkovoy V.A., Kolisnyk O.V. et al. // Вісник фармації. – 2015. – № 3 (83). – С. 76–78.
Zamorskii I.I., Sopova I.Yu., Khavinson V.Kh. // Bull. Exp. Biol. Med. – 2012. – Vol. 154, N. 1. – P. 51–53.
Copyright (c) 2016 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).